Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
Wenjin YinYaohui WangZiping WuYumei YeLiheng ZhouShuguang XuYanping LinYueyao DuTingting YanFan YangJie ZhangQiang LiuJingsong LuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The addition of pyrotinib to trastuzumab plus chemotherapy is an efficacious and safe regimen for patients with HER2-positive locally advanced breast cancer in the neoadjuvant setting. The randomized controlled clinical trial is warranted to validate our results.